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Introduction 
Achilles tendinosis is a common clinical painful condi-
tion characterized by pain during loading and appears 
both among elite athletes, as well as among adult persons 
with a sedentary lifestyle.1-3 Although it is a common clin-
ical condition, its causes and causal mechanisms are still 
unclear. The Achilles tendon pain, often long-term, does 
not always clearly reflect the pathological changes in the 
local tissue.4 The condition has been termed “tendonitis” 
and ”tendinitis,”5-8 indicating the possible association 
with acute inflammatory processes.9 Others2 did not find 
any signs of acute inflammation but increased amounts 
of inter-fibrillar glycosaminoglycans and changes in the 
collagen fibre structure, possibly accounting for a later 
stage in the inflammatory process; and the terms “degen-
erative changes,” “chronic tendinopathy” and “tendinosis” 
have been used. Furthermore, changes in the metabolism 
of the tendon cells, the tenocytes, and tissue remodeling 
based on interaction with biomarkers like neurotrophins 
and tumor necrosis factor alpha (TNF-α),10 has been re-
ported to contribute to the condition. Tendinosis is the 
chosen term in the present work since Alfredson and Lo-
rentzon2 suggested that the previously described terms 
could be used interchangeably, since they probably de-
scribe the same or almost the same condition. Multiple 
risks and possible predisposition factors for Achilles ten-
dinosis have recently been discussed, such as mal align-
ment in the lower extremity, reduced range of movement 
in the subtalar and the talocrural joints, increased fore-
foot pronation and inversion, decreased dorsal flexion 
with extended knee and varus deformation in the fore-
foot.11-14 Extrinsic factors such as change of load, intensity 
and distance in exercise programs could also be sources 
for development of the condition.15
Clinically, the diagnosis Achilles tendinosis is based on 
the medical history including the patients’ location of 
pain approx. 2-6 cm above the tendon insertion into the 
calcaneus bone, local pain by palpation and functional 
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Abstract
Introduction: Pain in the Achilles tendon during loading is a very common condition. 
Conservative treatments, such as low level laser therapy (LLLT) have been reported to give 
varying results. Recently, a new laser treatment technique, high power laser treatment 
(HPLT) (Swiss DynaLaser®), was introduced in Scandinavia, but has not, to our knowledge, 
been systematically tested before. The objective of this study was to evaluate the effects of 
HPLT compared to placebo HPLT in rated pain and assessed pain threshold in patients with 
chronic Achilles tendinosis.
Methods: The study was a randomized, single blind, placebo controlled trial. Patients were 
randomized to receive 6 treatments of either HPLT or placebo HPLT during a period of 
3-4 weeks with a follow up period of 8-12 weeks. Outcome measures were rated pain 
according to questions of the Foot and Ankle Outcome Score (FAOS, Swedish version 
LK1.0) and assessment of electro-cutaneous stimulated pain threshold and matched pain 
(PainMatcher). 
Results: The results of the study demonstrated significant changes of assessments within 
groups, that were more pronounced towards lower levels of rated pain in the HPLT group 
than in the placebo HPLT group. The between group difference were significant in four of 
nine questions regarding loading activities of the FAOS subscale. Assessed pain thresholds 
were found increased in the HPLT group, as compared to the placebo HPLT group. At 
individual level, the results varied. 
Conclusion: The results indicate that HPLT may provide a future option for treatment of 
Achilles tendinosis related pain, but further studies are warranted.
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testing. A common clinical finding is furthermore a pal-
pable sore nodular thickening in the tendon, 1.5-7.0 cm 
proximal to the insertion into the calcaneus bone.12 How-
ever, it appears that there is a lack of clear inclusion cri-
teria and consensus in how to diagnose chronic Achilles 
tendinosis. Hutchison et al16 suggested the use of muscu-
loskeletal ultrasound scanning (MSKUS) to be added for 
diagnose.
Multiple conservative types of treatment for Achilles ten-
dinosis have been reported, but the interpretation of its 
effects are complicated by the inconsistency of diagnos-
tic criteria. However, heavy load eccentric exercises ap-
pear to be an effective treatment modality, but seem to be 
time-consuming and difficult for some patients to comply 
with.2 Thus, it would be of value to find less time-con-
suming and less patient demanding treatments with ef-
fects on the perceived pain. Different types of laser treat-
ment could be an alternative. The effects of low level laser 
therapy (LLLT) have been described to influence inflam-
mation, angiogenesis, promote collagen synthesis and to 
reduce cell apoptosis.17 Thereby, the treatment can aid in 
recovery of the tendon injury,18-20 that in turn can contrib-
ute to decrease the related perceived pain, and possibly 
also increased activity in the endogenous pain inhibiting 
system. 
Recently, a newly developed laser technique, high power 
laser treatment (HPLT), based on a laser class 3B, infrared 
980 nm gallium arsenide laser, was introduced in Scandi-
navia for treatment of pain induced by musculoskeletal 
injuries. The HPLT is equipped with an electrical cooling 
system which allows delivery of higher energy levels in 
shorter time periods, compared to conventional laser sys-
tems. The wavelength is also of importance for the depth 
of penetration in tissue. Bjordal et al identified a thera-
peutic window for effect in the range of 2-10 J/cm² within 
810 to 830 nm wavelength,21 i.e. using Laser equipment 
with shorter wavelength than the HPLT. No established 
treatment protocol or evaluation of HPLT for pain treat-
ment in patients with Achilles tendinosis has been report-
ed earlier. 
The purpose of this study was to evaluate the changes in 
different aspects of pain, i.e. perceived pain frequency and 
intensity, in patients with long-term signs of Achilles ten-
dinosis, after treatment with HPLT (Swiss DynaLaser®) 
and placebo HPLT. The patients’ pain threshold and their 
physically matched pain were also assessed (see method 
section).
Methods
This was a randomized, single blind, placebo-controlled 
trial that was carried out within the framework of a Mas-
ter’s program and could, therefore, just receive an adviso-
ry opinion from the local ethical board in Stockholm, who 
stated that they could not see any ethical obstacle to the 
execution of the proposed project, dnr 2012/1985-31/1. 
Participants
The participants were recruited through three differ-
Table 1. Eligibility and Exclusion Criteria of Participating Patients
Eligibility
Age, 20-70 years
Pain from the Achilles tendon ≥2 months prior to treatment
Signed informed consent
MSKUS signs of Achilles tendinosis
Exclusion criteria
Other diseases or conditions: 
Malignant diseases; diabetes type 1 (polyneuropathy 
in the lower extremity); rheumatology diseases; acute 
inflammation near the Achilles tendon; monogenic familiar 
hypercholesterolemia; pregnancy 
Other treatments of the condition: 
Steroid injection 6 months before HPLT; extra corporal 
focused shockwave treatment 3 months before HPLT; earlier 
surgery; intake of NSAIDs 4 weeks before HPLT 
Abbreviations: HPLT, high power laser treatment; NSAIDs, non-
steroidal anti-inflammatory drugs; MSKUS, musculoskeletal 
ultrasound scanning.






Age (years), mean (SD) 47.4 (8.1)  41 (8.3)
Gender (w; m), n 12 w; 9 m 14 w; 7 m
MSK sign, n (%) 17 (89) 21 (100)
Achilles tendon (mm), mean (SD)
Longitudinal 7.4 (1.4) 6.7 (1.5)
Transversal 9.2 (3.8) 6.6 (2.3)
Oedema, n (%) 18 (95) 19 (90)
Tenderness by palpation, n (%) 18 (95) 21 (100)
Pain in heel lifting, n (%) 15 (79) 17 (81)
Abbreviation: HPLT, high power laser treatment.
ent methods: request to external physiotherapy clinics 
(n = 4), advertisement on social media sites for sport in-
juries, http://www.jogg.se/ (n = 24), http://www.funbeat.
se/ (n = 8), and from the first author’s clinic waiting-list 
(n = 6). All interested participants received the site ad-
dress to a specially designed website with background in-
formation, objective of the trial and the informed consent 
form (http://fysioterapiteamet.se/laserstudien.html). Par-
ticipants with symptoms of long-term Achilles tendinosis 
described in Table 1, were considered candidates for in-
clusion after giving their informed consent to participate. 
After approval of participation, the patients signed the 
informed consent at the first meeting. Forty-two patients 
were recruited consecutively. 
Randomization Procedure
Participants were randomized to either HPLT or placebo 
HPLT by randomly selecting one of two unmarked sealed 
envelopes. The baseline data of the randomized partici-
pants are presented in Table 2. The note inside the en-
velope was just marked A (placebo HPLT) or B (HPLT) 
without giving any information which group the two let-
ters represented. 
Physical Examination
The presence of Achilles tendinosis was defined as: an 
area of swelling in the Achilles tendon, tenderness of the 
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tendon during palpation, pain in the affected side during 
active heel lift standing on one leg, signs of tendinosis 
changes in MSKUS. Presence of three of these criteria 
confirmed the diagnosis.
Musculoskeletal Ultrasound Scanning 
MSKUS was performed by using a linear high frequency 
transducer (Prosonix MSK ultrasound scanner) applied 
to the skin with contact gel. Visions of the Achilles ten-
don, from musculo-tendinous junction to the distal in-
sertion on the calcaneus bone, were obtained in two or-
thogonal planes. The thickest point of the tendon in the 
transversal and longitudinal planes was noted. MSKUS 
measurements were made bilateral for comparison be-
tween the two sides.
Intervention
The HPLT or placebo HPLT was given at 6 sessions 
during 3-5 weeks. The placebo HPLT was distributed 
utilizing a second laser unit without active laser, but with 
visual and acoustic warning identical to the active HPLT 
equipment. The same physiotherapist (AM) treated all the 
participants. To maintain the participants blinding, both 
the HPLT unit and the placebo HPLT unit produced a 
sound and a visible red light during treatment and no in-
formation was communicated regarding group affiliation, 
i.e. all participants were given treatments under the same 
conditions. Before the first treatment, possible side effects 
were presented to the participants stating they could feel 
warmth, rubbing, tingling or some discomfort and they 
were asked to avoid any eccentric exercise during inter-
vention and follow up periods. During the treatments, the 
participants were placed in a prone position with extend-
ed hip and knee, and the ankle in maximal dorsal flexion. 
High Power Laser Treatment Equipment 
The treatment protocol was chosen on the basis of rec-
ommendations from the manufacturer and AM’s clinical 
experience, Table 3. For the HPLT, Swiss DynaLaser® in-
frared 980 nm gallium arsenide laser equipment was used. 
The HPLT was delivered with skin contact and slight 
pressure on 5 points per side over the painful area, which 
was repeated twice each session. First round/session was 
delivered with 17 J/point and a second round/session was 
delivered with 35 J/point. Total energy delivered per ses-
sion was 520 J (Manufacturer: HP-Swiss Medical; info@
hp-medical.com), Table 3. For placebo HPLT a second 
unit without active laser was used with all other proce-
dures identical to the active HPLT.
Outcome Measures
The participants rated their pain (frequency and intensi-
ty), assessed their pain threshold and their matched pain, 
at baseline and at 8-12 weeks follow-up after the random-
ization.
Rated Pain
The five verbal category Pain subscales of the self-as-
sessment form Foot and Ankle Outcome Score (FAOS) 
(Swedish version LK1.0) was used for assessment of the 
perceived pain in different situations. The pain subscale 
consists of nine different questions where the first ques-
tion is related to the frequency of perceived pain (How of-
ten do you experience foot/ankle pain?), which responses 
are: Never, Monthly, Weekly, Daily, Always. The remain-
ing 8 questions relate to the experienced intensity of the 
pain during the last week, which was rated by the follow-
ing verbal alternatives – None, Mild, Moderate, Severe, 
Extreme. In the data sheet the categories were recorded 
as 0 to 4.
Pain Threshold and Matched Pain
Pain threshold and perceived matched pain were assessed 
utilizing the instrument PainMatcher (PainMatcher®, 
Cefar Medical AB, Lund, Sweden) that has shown good 
reliability and validity.22,23 PainMatcher gives an elec-
tro-cutaneous stimulation to the skin of two fingers, the 
index finger and the thumb in one hand. The increase in 
the constant current generation of the PainMatcher is in-
terrupted when the person releases the fingers from the 
stimulation electrode and a value, PM value, between 0 
and 99 (arbitrary units but directly related to the pulse 
width) is displayed on the LCD screen on the instrument. 
The pain threshold is assessed when the patient experi-
ences the least sensation of pain. Matched pain is assessed 
when the patient feels that the intensity of the electric-cu-
taneous sensation matches the actual pain intensity expe-
rienced in the Achilles tendon. 
Statistical Methods
The mean value and standard deviation (SD) were calcu-
lated for quantitative variables, and rated experiences were 
Table 3. Technical/Treatment Data With HPLT (Swiss DynaLaser®)
Technical Data
Voltage 230 V AC
Frequency 50 Hz
Current 2.85 Amp
Output Infrared 980 nm/660 nm, 
Gallium Arsenide
Output 0.1 n 9.9 KHz/0.25-35 J/
cm2
ON/OFF Key switch/Footswitch
Warning/CE Visual and acoustic warning 
tone/0123
Treatment data
Irradiation area spot size 0.78 cm²
Wavelength 980 nm
Number of irradiation points 10 x 2 rounds
Energy/point in first round 17 J
Energy/point in second round 35 J
Total energy/session 520 J
Total energy in 6 sessions 3120 J
Irradiation technique Skin contact, slight pressure 
on 10 points on each side 
over painful area repeated 
twice/session
Abbreviation: HPLT, high power laser treatment.
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given as median and range (minimum to maximum). The 
pattern of change in the paired assessments between base-
line and follow-up are described in Table 4, Figures 1 and 
2 while pain threshold and matched pain are described 
in scatterplots, Figures 2 and 3. The main diagonal in the 
scatter plots from the lower left corner to the upper right 
indicates no change between the two occasions. Results 
below the diagonal means lower pain threshold or lower 
matched pain after treatment. 
For analysis of changes within and between the groups, 
the method by Svensson was used.24,25 A measure of sys-
tematic change in the paired assessments (before and at 
follow-up), related to the respective group, was calculat-
ed and is named relative position (RP). Possible values of 
RP range from -1 to 1. Values close to zero indicate lack 
of systematic group change. Negative RP values indicate 
systematic group change towards lowered assessed levels 
at follow-up. Additional individual variations in change 
that is unexplained by the RP value, are expressed by the 
RV (relative rank variance), ranging from 0 to 1 (no ad-
ditional individual changes to complete additional indi-
vidual changes). The RP and RV with their 95% CI)were 
calculated.24,25 Statistically significant measures are evi-
dent by CIs not covering zero value. Analyses of possible 
differences in systematic changes in assessments between 
groups, Δ RP, was also calculated. Two-sided P<0.05 cor-
rected with Bonferroni-Holm adjustment for multiple 
tests26 was regarded as significant. Statistica 12 (Statsoft®, 
USA) was used for descriptive statistics and Excel macro 
was used for the analysis with the method by Svensson.25
Drop out
Of the eligible patients, 4 of them (2 patients from each 
group) dropped out. One patient in the placebo HPLT 
group dropped out without explanation and one patient 
was not willing to stop with eccentric exercises. One pa-
tient in the HPLT group chose not to continue before 
starting treatment without any explanation and one pa-
tient did not show up at follow up. The patient contact-
ed the clinic later and explained that not showing up was 
pure oblivion, Figure 4.
Results
Of the 40 included patients, 25 women and 15 men, with 
a mean age of 43.8 (9.1) years, 19 were randomized to the 
placebo HPLT group and 21 to the HPLT group. The di-
agnostic signs of swelling, tenderness by palpation, pro-
voked pain in the local area by heel lifting in standing 
on one leg and ultrasounds scanning were present in a 
majority of the patients in both groups. Furthermore, the 
MSKUS assessments demonstrated signs of tendinosis 
changes in 17 patients (89%) in the placebo HPLT group 
and 21 patients (100%) in the HPLT group, Table 1.
Pain
The first question in the pain subscale, “How often,” was 
rated significantly lower by the patients in the HPLT 
group at follow-up (median: Weekly, range: never to 
weekly) as compared to the patients in the placebo HPLT 
group (median: Daily, range: weekly to always), P = 0.001. 
The responses to “Bending fully,” “Walking on flat sur-
face” and “Standing upright,” showed similar differences 
in change of rated painful aspects between the groups 
(Table 4, Figure 1). 
Pain Threshold
As evident from Figure 2, the assessed pain threshold was 
decreased or unchanged in three of 18 individuals in the 
HPLT group and in nine of 17 individuals in the place-
bo HPLT group after treatment. Significant change in the 
assessed pain threshold towards higher values was found 




















































Figure 1. Relative Position (RP) Profiles of Self-rated Pain Items of the Foot and Ankle Outcome Score (FAOS).
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additional individual variations, RV 0.35 (95% CI: 0.00 to 
0.69). No such systematic group change was found in the 
placebo HPLT group, RP -0.02 (95% CI: -0.22 to 0.17). 
The observed changes are attributed to individual vari-
ations, RV 0.17 (95% CI: 0.03 to 0.30). The difference in 
systematic changes in pain threshold between groups, Δ 
RP, was 0.370, P = 0.015 (Figure 2).
Matched Pain
Matched pain values were found significantly lower in the 
HPLT group, n = 18, at follow up RP -0.65 (95% CI: -0.94 
to -0.36) with large individual variation, RV 0.46 (95% 
CI: 0.00 to 1.00). Corresponding individual variations 
were found in the Placebo HPLT group, RV 0.60 (95% CI: 
0.04 to 1.00), but systematic change was not evident, RP 
-0.27 (95% CI: -0.54 to 0.01) (Figure 3). The observed dif-
ference in systematic changes in matched pain between 
groups, Δ RP -0.385, indicated weak statistical evidence of 
significant difference between the groups, P = 0.06.
Discussion
The results of this single-blind randomized clinical study 
provides evidences that the patients subjected to HPLT 
rated significantly less pain in four of nine questions of 
the FAOS pain subscale (pain: how often, when bending 
fully, walking on flat surface, when standing upright) as 
compared to the patients treated with placebo HPLT at 
follow-up after treatment. Furthermore, the pattern of 
change showed that the pain-thresholds were signifi-
cantly higher among the HPLT patients at the group level 
than among the placebo HPLT patients, when comparing 
the follow-up with the base-line assessments. The results 
also demonstrated different response patterns among the 
individual patients within the two groups, confirmed by 
great RV values with wide confidential intervals. These 
individual based variations may indicate that treatments 
may need to be tailored to the individual regarding e.g. 
duration of treatment, number of treatments, etc. The de-
crease in perceived pain and increase in pain thresholds 
in the HPLT group could be a sign of increased activity 
in the endogenous pain inhibitory system as a response 
to the sensory stimulation evoked by this type of laser 
therapy. 
In this study, pain was rated lower already at 8 weeks after 
Figure 2. Paired Data of Pain Threshold Assessment Given as PainMatcher (PM) Values for the Two Groups Respectively. 
Figure 3. Paired Data of Matched Pain Assessment Given as PainMatcher (PM) Values for the Two Groups Respectively. 
Placebo HPLT
0 5 10 15 20 25 30 35




























0 5 10 15 20 25 30




























0 5 10 15 20 25 30 35



























0 5 10 15 20 25 30 35



























Journal of Lasers in Medical Sciences  Volume 7, Number 2, Spring 2016 97
                                                                  High Power Laser for Treatment of Achilles Tendinosis
start of treatment compared to previous studies that have 
reported reduced pain after 12 weeks of treatment.2,27 In 
a study with LLLT in patients with Achilles tendinosis, a 
small rise in pressure pain threshold was seen as well as 
immediate decreased concentrations of prostaglandin E2 
in peritendinous tissue,17 indicating changes in inflam-
matory reactions, possibly associated with changed func-
tion in the pain system. However, the effects of HPLT on 
Achilles tendinosis induced pain have not been published 
earlier. 
An interesting finding was that three of the pain ques-
tions, all related to loading the Achilles tendon (Bending 
fully, Walking on flat surface, Standing upright), were rat-
ed lower by the HPLT patients than the placebo HPLT 
patients. However, there was no significant difference be-
tween groups in responses to question of pain in: Twist-
ing/pivoting, Straightening fully, At night while in bed, 
Sitting or lying). This observation indicates that it would 
be of value to develop more specific selection of pain re-
lated questions in order to catch treatment responses of 
HPLT in patients with Achilles tendinosis. 
Bagge10 found significant increased levels of neurotroph-
in and TNF-α in tendons with chronic Achilles tendino-
sis. Bagge suggested that the functions of these substances 
include apoptosis, tissue remodeling, and proliferation in 
tenocytes. In future studies, it would be interesting to also 
measure changes in the levels of neurotrophin and TNF-α 
in response to HPLT in patients with chronic Achilles 
tendinosis. A wide variety of interventions for Achilles 
tendinosis have been utilized earlier where some of the 
methods are quite demanding regarding the patients 
Table 4. Data of Rated Pain From the Subscale of the FAOS Questionnaire Shown as Median (Min-Max)a
Questions of FAOS 
Subgroup
Placebo HPLT, n=17 HPLT, n=18
Base-Line Follow-up RP (95% CI)
RV (95% CI)
Base-Line Follow-up RP (95% CI)
RV (95% CI)




3 (2-4) 3 (0-4)
-0.31 (-0.55 to -0.07) 
0.11 (0.00 to 0.28)
3 (2-4) 2 (0-2)
-0.76 (-0.92 to -0.59) 





1 (0-3) 0 (0-3)
-0.21 (-0.39 to -0.04) 
0.16 (0.00 to 0.40)
1 (0-3) 0 (0-3)
-0.49 (-0.67 to -0.31) 
0.02 (0.00 to 0.07)
-0.28; 
P = 0.126
3. Straightening fully 1 (1-3) 1 (1-2)
-0.15 (-0.33 to 0.02) 
0.04 (0.00 to 0.14)
1 (0-4) 0 (0-2)
-0.45 (-0.63 to -0.26) 
0.02 (0.00 to 0.05)
-0.30; 
P = 0.054
4. Bending fully 1 (0-2) 1 (0-2)
-0.18 (-0.36 to 0.01) 
0.02 (0.00 to 0.07)
1 (0-3) 0 (0-3)
-0.51 (-0.69 to -0.32) 
0.00 (0.00 to 0.00)
-0.33; 
P = 0.048
5. Walking on flat 
surface
1 (0-4) 1 (0-3)
-0.11 (-0.29 to 0.06) 
0.16 (0.00 to 0.42)
2 (0-4) 0 (0-3)
-0.47 (-0.66 to -0.29) 
0.11 (0.00 to 0.33)
-0.36; 
P = 0.029
6. Going up or down 
stairs
2 (0-3) 1 (0-3)
-0.35 (-0.52 to -0.17) 
0.46 (0.00 to 0.93)
2 (0-3) 1 (0-3)
-0.57 (-0.75 to -0.38) 
0.20 (0.00 to 0.42)
-0.22; 
P = 0.285
7. At night while in 
bed
0 (0-3) 0 (0-2)
-0.11 (-0.28 to 0.07) 
0.00 (0.00 to 0.00)
0 (0-4) 0 (0-2)
-0.03 (-0.21 to -0.05) 
0.01 (0.00 to 0.02)
-0.08;
P = 0.936
8. Sitting or lying 0 (0-3) 0 (0-1)
-0.13 (-0.31 to 0.05)
0.01 (0.00 to 0.05)
0 (0-3) 0 (0-3)
-0.23 (-0.42 to -0.05) 
0.01 (0.00 to 0.04)
-0.10; 
p=0.465
9. Standing upright 0 (0-3) 1 (0-3)
0.16 (-0.02 to 0.33) 
0.07 (0.00 to 0.22)
1 (0-3) 0 (0-3)
-0.52 (-0.71 to -0.34) 
0.14 (0.00 to 0.37)
-0.36; 
P < 0.0001
Abbreviation: FAOS, Foot and Ankle Outcome Score.
a Systematic group changes are shown as RP (95%CI) and individual variability (dispersion in change) as RV (95%CI) from the Svensson 
method. Response alternative to question 1: Never (0), Monthly (1), Weekly (2), Daily (3), Always (4); question 2-9: None (0), Mild (1), 
Moderate (2), Severe (3), Extreme (4).
Figure 4. Flow Chart of Participating Patients
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compliance.27 The most optimized treatment method for 
the condition is not yet established. 
There are some limitations in the current study. One lim-
itation is the low number of participants in each group 
and that the patients were heterogeneous regarding ac-
tivity level, symptom duration, age and gender. Another 
limitation was that the therapist was not blinded to the 
patients’ allocation to different groups, since the active 
laser unit was also used in daily clinic routine and there-
by not possible to blind the therapist. However, actions to 
secure valid routines during the study were taken by not 
communicating information with the patients beyond a 
standardized manuscript.
Conclusion
The result of this study demonstrated that patients with 
painful Achilles tendinosis treated with high power laser 
rated lower pain and assessed higher pain threshold at fol-
low-up after the treatment in comparison with patients 
treated with placebo high power laser. HPLT may provide 
a future option for treatment of Achilles tendinosis, but 
further studies are warranted.
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